Please use this identifier to cite or link to this item:
|Title:||AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients.|
|Authors:||Martin, Kevin J;Pickthorn, Karen;Huang, Saling;Block, Geoffrey A;Vick, Andrew;Mount, Peter F;Power, David Anthony;Bell, Gregory|
|Affiliation:||Division of Nephrology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.|
Amgen, Inc, Thousand Oaks, California, USA.
Denver Nephrology, Denver, Colorado, USA.
WIL Research, Ashland, Ohio, USA.
Austin Hospital, Melbourne, Victoria, Australia.
1] Amgen, Inc, Thousand Oaks, California, USA  University of California, San Francisco, California, USA.
|Citation:||Kidney International 2013; 85(1): 191-7|
|Abstract:||AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, lowers plasma parathyroid hormone in preclinical uremic animal models and in normal healthy individuals. Here, we studied its efficacy in hemodialysis patients suffering from secondary hyperparathyroidism. Major inclusion criteria were hemodialysis for at least 3 months, serum parathyroid hormone over 300 pg/ml, a corrected serum calcium of 9.0 mg/dl or more, and stable doses of vitamin D analogs for at least 3 weeks prior to screening. Twenty-eight patients were enrolled in one of five cohorts (5, 10, 20, 40, 60 mg). Cohorts 1-3 (four patients each) were treated in a two-period crossover design, while cohorts 4 and 5 (eight patients each) were randomized 1:1 to AMG 416 or placebo. Patients were admitted to a clinical research unit following hemodialysis and studied for 3 days prior to discharge for hemodialysis. Single intravenous doses of AMG 416 from 5 to 60 mg were well tolerated, and plasma levels increased in a dose-related manner. AMG 416 treatment was associated with significant, dose-dependent reductions in serum parathyroid hormone and fibroblast growth factor 23. Compared with placebo, all dose groups of 10 mg or more were associated with attenuation in the rise in serum phosphate during the interdialytic period. Dose-dependent reductions in serum calcium were observed and were well tolerated. Thus, AMG 416 represents a novel therapeutic approach for the treatment of secondary hyperparathyroidism in hemodialysis patients.|
|Internal ID Number:||23903371|
Aged, 80 and over
Hyperparathyroidism, Secondary.drug therapy
Kidney Failure, Chronic.complications.therapy
Peptides.administration & dosage.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.